Measurement of cardiovascular and pulmonary function endpoints and other physiological effects following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

Regulatory Toxicology and Pharmacology

Volumn 87, Issue , 2017, Pages 36-53

  D'Ruiz, Carl D ^a   O'Connell, Grant ^b   Graff, Donald W ^c   Yan, X Sherwin ^d  

^a Fontem Ventures   (United States)

^b Fontem Ventures   (Netherlands)

^c CELERION   (United States)

^d LORILLARD TOBACCO COMPANY   (United States)

Author keywords

Adverse effects; Cardiovascular effects; E cigarette; Exclusive and dual use; Harm reduction; Physiological effects; Pulmonary effects

Indexed keywords

CARBON MONOXIDE; NICOTINE; NITRIC OXIDE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELECTRONIC CIGARETTE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART RATE MEASUREMENT; HUMAN; HUMAN EXPERIMENT; LUNG FUNCTION TEST; MALE; NORMAL HUMAN; SMOKING; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TOBACCO; VITAL SIGN; BLOOD PRESSURE; FORCED EXPIRATORY FLOW; HEART RATE; LUNG; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TOBACCO DEPENDENCE; VITAL CAPACITY;

ADULT; BLOOD PRESSURE; ELECTRONIC NICOTINE DELIVERY SYSTEMS; FORCED EXPIRATORY FLOW RATES; HEART RATE; HUMANS; LUNG; RESPIRATORY FUNCTION TESTS; SMOKING; SMOKING CESSATION; TOBACCO PRODUCTS; TOBACCO USE DISORDER; VITAL CAPACITY;

EID: 85018412578     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2017.05.002     Document Type: Article

References (71)

1. Benowitz, N.L., Burbank, A.D., Cardiovascular toxicity of nicotine: implications for electronic cigarette use. Trends Cardiovasc Med. 26:6 (2016), 515–523, 10.1016/j.tcm.2016.03.001 Aug.
2. Benowitz, N.L., et al. Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension 39 (2002), 1107–1112.
3. Bowman, T.S., et al. A prospective study of cigarette smoking and risk of incident hypertension in women. J. Am. Coll. Cardiol., 50, 2007, 2085.
4. Callahan-Lyon, P., Electronic cigarettes: human health effects. Tob. control, 23(Suppl. 2), 2014, 2014 ii36-40.
5. Callahan-Lyon, P., Nicotine Replacement Therapy: the CDER Experience. 2016, US FDA (Accessed 21 November 2016) http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/TobaccoProductsScientificAdvisoryCommittee/UCM288284.pdf (last Accessed on 7 August 2016).
6. Caponnetto, P., et al. EffiCiency and safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One, 8(6), 2013.
7. Caponnetto, P., et al. Successful smoking cessation with electronic cigarettes in smokers with a documented history of recurring relapses: a case series. J. Med. Case Rep., 5, 2011, 585.
8. Chambers, D.C., et al. Acute inhalation of cigarette smoke increases lower respiratory tract nitric oxide concentrations. Thorax 53:8 (1998), 677–679 August.
9. Cibella, F., et al. Lung function and respiratory symptoms in a randomized cessation trial of electronic cigarettes. Clin. Sci., Aug 19, 2016, 10.1042/CS20160268 http://www.clinsci.org/content/early/2016/08/19/CS20160268.
10. D'Ruiz, C.D., et al. Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes. BMC Public Health, 16(543), 2016, 10.1186/s12889-016-3236-1.
11. D'Ruiz, C.D., et al. Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes. BMC Public Health, 15, 2015, 991, 10.1186/s12889-015-2349-2.
12. Deveci, S.E., et al. The measurement of exhaled carbon monoxide in healthy smokers and non-smokers. Resp. Med. 98:6 (2004), 551–556.
13. Eberly, L.E., et al. Multiple Risk Factor Intervention Trial Research Group. Pulmonary function as a predictor of lung cancer mortality in continuing cigarette smokers and in quitters. Int. J. Epidemiol. 32:4 (2003), 592–599 Aug.
14. Fabricius, P., et al. Exhaled CO, a predictor of lung function?. Respir. Med. 101:3 (2007), 581–586.
15. Fagerström, K., Determinants of tobacco use and renaming the FTND to the Fagerström test for cigarette dependence. Nicot. Tob. Res. 14:1 (2012), 75–78.
16. Farsalinos, et al. Immediate effects of electronic cigarette use on coronary circulation and blood carboxyhemoglobin levels: comparison with cigarette smoking. Eur. Heart J., 34(Abstract Supplement), 2013, 13.
17. Farsalinos, K.E., Polosa, R., Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther. Adv. Drug Saf. 5:2 (2014), 67–86.
18. Farsalinos, K.E., et al. Acute effects of using an electronic nicotine-delivery device (electronic cigarette) on myocardial function: comparison with the effects of regular cigarettes. BMC Cardiovasc. Disord., 14, 2014, 78.
19. Farsalinos, K.E., et al. Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers. Int. J. Env. Res. Public Health 11:4 (2014), 4356–4373.
20. Farsalinos, K., et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Intern. Emerg. Med. 11:1 (2016), 85–94.
21. Federal Trade Commission (FTC), 2006 and 2007 FTC Tar, Nicotine, and Carbon Monoxide Reports. Released under the Freedom of Information Act on May 15, 2012, 2012 (Accessed 9 September, 2016) http://www.econdataus.com/smoke.html.
22. Flouris, A.D., et al. Acute impact of active and passive electronic cigarette smoking on serum cotinine and lung function. Inhal. Toxicol. 25:2 (2013), 91–101.
23. Glaab, T., et al. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir. Res., 11, 2010, 79.
24. Goniewicz, M.L., et al. Exposure to nicotine and selected toxicants in cigarette smokers who switched to electronic cigarettes: a longitudinal within-subjects observational study. Nicot. Tob. Res., 2016, 1–8, 10.1093/ntr/ntw160.
25. Goniewicz, M.L., et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob. Control 23:2 (2014), 133–139.
26. Green, M.S., et al. Blood pressure in smokers and nonsmokers: epidemiologic findings. Am. Heart J., 111, 1986, 932.
27. Groppelli, A., et al. Persistent blood pressure increase induced by heavy smoking. J. Hypertens., 10, 1992, 495.
28. Gross, N.J., 2005. Chronic Obstructive Pulmonary Disease Outcome Measurements, Proceedings of the American Thoracic Society, Vol. 2, Symposium: The science of COPD: opportunities for combination therapy. pp. 267–271.
29. Hajek, P., et al. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction 109:11 (2014), 1801–1810, 10.1111/add.12659.
30. Hajek, P., et al. Nicotine intake from electronic cigarettes on initial use and after 4 Weeks of regular use. Nicot. Tob. Res. 17:2 (2014), 175–179.
31. Heatherton, T.F., et al. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br. J Addict. 86:9 (1991), 1119–1127.
32. Hecht, S.S., et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicot. Tob. Res. 7:6 (2015), 704–709.
33. Hogman, M., et al. Increased nitric oxide elimination from the airways after smoking cessation. Clin. Sci. Lond. 103:1 (2002), 15–19 July.
34. IARC, Agents Classified by the IARC Monographs. 2016, International Agency for Research on Cancer Volumes 1 – 114. 2015. (Accessed 21 November 2016) http://monographs.iarc.fr/ENG/Classification/List_of_Classifications_Vol1-114.pdf.
35. Jarvis, J.M., Expired air carbon monoxide: a simple breath test of tobacco smoke intake. BMJ, 2, 1980, 484.
36. Kannel, W.B., Elevated systolic blood pressure as a cardiovascular risk factor. Am. J. Cardiol. 85:2 (2000), 251–255.
37. Kharitonov, S.A., et al. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am. J. Resp. Crit. Care Med. 152:2 (1995), 609–612.
38. Li, Y., et al. Cardiovascular risks associated with diastolic blood pressure and isolated diastolic hypertension. Curr. Hypertens. Rep. 16:11 (2014), 1–6.
39. Malinovschi, A., et al. Effect of smoking on exhaled nitric oxide and flow-independent nitric oxide exchange parameters. Eur. Respir. J. 28:2 (2006), 339–345.
40. McNeill, A., et al. E-cigarettes: an evidence update – a report commissioned by Public Health England. 2015, Public Health England 111. (Accessed 21 November 2016) www.gov.uk/government/uploads/system/uploads/attachment_data/file/454516/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England.pdf.
41. McRobbie, H., et al. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst. Rev., 12, 2014, CD010216, 10.1002/14651858.CD010216.pub2.
42. Mikkelsen, K.L., et al. Smoking related to 24-h ambulatory blood pressure and heart rate: a study in 352 normotensive Danish subjects. Am. J. Hypertens., 10, 1997, 483.
43. Najem, B., et al. Acute cardiovascular and sympathetic effects of nicotine replacement therapy. Hypertension, 47, 2006, 1162.
44. Nelson, V.A., et al. Comparison of the characteristics of long-term users of electronic cigarettes versus nicotine replacement therapy: a cross-sectional survey of English ex-smokers and current smokers. Drug Alcohol Depend. 153 (2015), 300–305.
45. Nides, M.A., et al. Nicotine blood levels and short-term smoking reduction with an electronic nicotine delivery system. Am. J. Health Behav. 38:2 (2014), 265–274.
46. Nutt, D.J., et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur. Addict. Res. 20:5 (2014), 218–225.
47. O'Connell, G., et al. Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers. Toxicol. Mech. Meth., 2016, 1–12 http://www.tandfonline.com/doi/full/10.1080/15376516.2016.1196282.
48. Palatini, P., Julius, S., Elevated heart rate: a major risk factor for cardiovascular disease. Clin. Exp. Hypertens. 26 (2004), 637–644.
49. Papathanasiou, G., et al. Effects of smoking on cardiovascular function: the role of nicotine and carbon monoxide. Health Sci. J. 8:2 (2014), 272–288.
50. Pastor-Barriuso, R., et al. Systolic blood pressure, diastolic blood pressure, and Pulse pressure: an evaluation of their joint effect on mortality. Ann. Intern. Med. 139:9 (2003), 731–739.
51. Perret-Guillaume, C., et al. Heart rate as a risk factor for cardiovascular disease. Prog. Cardiovasc. Dis. 52:1 (2009), 6–10.
52. Polosa, R., et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Intern. Emerg. Med. 9:5 (2014), 537–546.
53. Polosa, R., Electronic cigarette use and harm reversal: emerging evidence in the lung. BMC Med. 13:54 (2015), 10–13 http://www.biomedcentral.com/1741-7015/13/54.
54. Ripoll, J., et al. Clinical trial on the efficacy of exhaled carbon monoxide measurement in smoking cessation in primary health care. BMC Public Health, 12, 2012, 322.
55. Robbins, R.A., et al. Smoking cessation is associated with an increase in exhaled nitric oxide. Chest 112:2 (1997), 313–318 August.
56. Royal College of Physicians, Nicotine without smoke, tobacco harm reduction – a report by the tobacco advisory group of the royal College of physicians. (Accessed 21 November 2016) https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobacco-harm-reduction-0, 2016.
57. Singh, B.N., Increased heart rate as a risk factor for cardiovascular disease. Eur. Heart J. 5:Suppl. G (2003), G3–G9.
58. Smith, S.S., et al. Development of the brief Wisconsin inventory of smoking dependence motives. Nicot. Tob. Res. 12:5 (2010), 489–499.
59. Tantisuwat, A., Thaveeratitham, P., Effects of smoking on chest expansion, lung function, and respiratory muscle strength of youths. J. Phys. Ther. Sci. 26:2 (2014), 167–170.
60. Taylor, D.R., et al. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 61:9 (2006), 817–827 http://doi.org/10.1136/thx.2005.056093.
61. Tayyarah, R., Long, G.A., Comparison of select analytes in aerosol from e-cigarettes with smoke from conventional cigarettes and with ambient air. Reg. Toxicol. Pharmacol., 2014 http://dx.doi.org/10.1016/j.yrtph.2014.10.010.
62. U.S. Department of Health and Human Services, The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General, 2014, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta (Accessed 21 November 2016) https://www.surgeongeneral.gov/library/reports/50-years-of-progress.
63. USFDA, Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke: Established List. 2012, U.S. Food and Drug Administration (Accessed 21 November 2016) www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm.
64. Van Staden, S.R., et al. Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes. S Afr. Med. J. 103.11 (2013), 865–868.
65. Vansickel, A.R., Eissenberg, T., Electronic cigarettes: effective nicotine delivery after acute administration. Nicot. Tob. Res. 15:1 (2013), 267–270.
66. Vestbo, J., Lange, P., Natural history of COPD: focusing on change in FEV1. Respirology 21:1 (2016), 34–43, 10.1111/resp.12589 Jan.
67. Walele, T., et al. A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics. Reg. Toxicol. Pharmacol. 74 (2016), 187–192, 10.1016/j.yrtph.2015.12.003.
68. Walele, T., et al. A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part B: safety and subjective effects. Reg. Toxicol. Pharmacol. 74:2 (2016), 187–192.
69. West, R., et al. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 100 (2005), 299–303.
70. Yan, X.S., D'Ruiz, C.D., Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. Reg. Toxicol. Pharmacol. 71:1 (2015), 24–34, 10.1016/j.yrtph.2014.11.004 Feb.
71. Zevin, S., et al. Cardiovascular effects of carbon monoxide and cigarette smoking. J. Am. Coll. Cardiol. 2001:38 (2001), 1633–1638.